Merck (NYSE: MRK) presented results from three Phase 3 trials evaluating an investigational HIV-1 treatment combining doravirine and islatravir at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE